Ayeshia Wright
Nurse Practitioner · Mocksville, NCNPI 1215485867
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.0%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Sanofi accounts for 75.2% of it on its own, with 31 other manufacturers making up the rest. Among nurse practitioner clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 569 payments — averaging $254.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$109K
- Regeneron Healthcare Solutions, Inc.$20K
- GSK$10K
- AstraZeneca$3K
- Amgen$628
- Mylan Specialty L.p.$310
- plus $1K from 26 others
What the payments were for
- Consulting fees$13,98110%
- Speaking & faculty fees$83,91258%
- Travel & lodging$32,83723%
- Food & beverage$13,7449%
- Education$2910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 198 | $108,865 |
| Regeneron Healthcare Solutions, Inc. | 58 | $19,807 |
| GSK | 123 | $10,465 |
| AstraZeneca | 61 | $3,295 |
| Amgen | 49 | $628 |
| Mylan Specialty L.p. | 14 | $310 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $108 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Insmed, Inc. | 5 | $97 |
| Actelion Pharmaceuticals US, Inc. | 4 | $93 |
| Grifols USA, LLC | 4 | $84 |
| Inogen, Inc. | 5 | $79 |
| ANI Pharmaceuticals, Inc. | 4 | $76 |
| Baxter Healthcare | 3 | $74 |
| Inspire Medical Systems, Inc. | 2 | $69 |
| Novartis | 3 | $65 |
| Advanced Respiratory, Inc | 3 | $61 |
| Lilly USA, LLC | 3 | $61 |
| Viatris Specialty LLC | 3 | $55 |
| Genentech USA, Inc. | 2 | $48 |
| Merck | 2 | $44 |
| Electromed, Inc. | 3 | $43 |
| Phadia US Inc. | 2 | $42 |
| Boehringer Ingelheim | 2 | $36 |
| Hikma Pharmaceuticals USA | 2 | $31 |
| Paratek Pharmaceuticals, Inc. | 2 | $29 |
| Aytu Biopharma, Inc. | 1 | $21 |
| ADMA Biomanufacturing LLC | 1 | $20 |
| Philips North America LLC | 1 | $17 |
| Pfizer | 1 | $15 |
| Masimo Corporation | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$144,765 in reported general payments places this provider in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 694 | $510,167 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 137 | $93,423 |
| Fasenra PenBenralizumab | 17 | $93,299 |
| Dupixent PenDupilumab | 21 | $79,702 |
| TezspireTezepelumab-Ekko | 12 | $51,964 |
| Ambrisentan | 21 | $47,000 |
| Breo ElliptaFluticasone/Vilanterol | 68 | $32,670 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 45 | $27,706 |
| EliquisApixaban | 19 | $18,582 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $12,329 |
| Spiriva RespimatTiotropium Bromide | 18 | $9,286 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 260 | $7,076 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $6,162 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $2,666 |
| Famotidine | 242 | $2,504 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $10,465 | $555,166789 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $3,295 | $151,549174 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $36 | $36,99263 claims |
| PfizerEliquis | $15 | $18,58219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.
Other nurse practitioner in Mocksville
- Sandrivette JohnsonRaleigh$573K
- Jeanann VawterGastonia$97K
- Terra KampJacksonville$72K
- Mary DilorenzoCharlotte$71K
- Olivia OgburnWinston Salem$70K
- Bridget ArchambaultDurham$57K
- Deborah MayerChapel Hill$55K
- Amber SeilerGreensboro$55K
- Stephanie PascaleRaleigh$54K
- Joseph WilkinsonSmithfield$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.